Cancer is an insidious disease. Even after surgery or aggressive systemic therapy, malignant cells often take refuge in hard-to-identify places in the body before emerging again to cause recurring illness. For many years, researchers have been looking for more effective, less invasive ways to spot residual cancer cells after therapy to better gauge the impact […] The post Capturing circulating tumor data in RWD: A new frontier for cancer research appeared first on COTA Healthcare.| COTA Healthcare
We sat down with COTA’s Senior Statistical Director (and former FDA insider), Laura Fernandes, to discuss what trends pharma companies should watch over the next few months.| COTA Healthcare
Transforming Cancer Care Through Data COTA provides oncology research and development, regulatory, commercial, and HEOR teams with detailed real-world patient data to discover new treatment protocols and transform cancer care. Learn More Powering the Next Generation of Cancer Research Real, longitudinal patient data across dozens of patient subgroups and oncology disease areas help pharmaceutical and […]| COTA Healthcare
Real-world data (RWD) from electronic health records (EHRs) is increasingly recognized as a powerful asset for oncology research. It enables stakeholders across industry and academia to evaluate treatment patterns, assess comparative effectiveness, identify safety signals, and inform regulatory and market access strategies. RWD has supported external control arms, augmented clinical trial enrollment, and generated post-marketing […]| COTA Healthcare
Get in touch Contact COTA Have a question? We’re here to help! Transforming Healthcare Contact COTA Have a question or need assistance? We’re here to help! General Inquiries Send us an email hello@cotahealthcare.com Media Inquiries Send us an email pr@cotahealthcare.com Headquarters 200 Varick Street, Suite 503 New York, NY 10014 Get Early Access to Innovation […]| COTA Healthcare
At COTA, we believe the future of healthcare is shaped not only by innovation and data but by people. Each summer, we’re excited to welcome a group of bright, driven interns who bring fresh perspectives, unique talents, and a shared passion for meaningful impact. This year is no exception. Our 2025 intern class includes students […] The post Welcoming the Next Generation: COTA’s 2025 Summer Interns appeared first on COTA Healthcare.| COTA Healthcare
We sat down with COTA’s Chief Medical Officer and oncologist, Dr. C.K. Wang, to discuss solid-tumor RWD – and how combining it with powerful artificial intelligence (AI) models will support drug development for people with cancer.| COTA Healthcare
News COTA in the News At COTA, we are dedicated to fostering a supportive and dynamic work environment.We believe in empowering our employees to make a difference in the lives of patients and their families. Join us and be part of a team that is revolutionizing healthcare. Awards & Recognition COTA News Press Releases Team […]| COTA Healthcare
Four Ways Pharmaceutical Companies Are De-Risking R&D with Real-World Data Pharmaceutical research and development is inherently complex and high-risk. Sponsors must ensure that investigational products demonstrate both strong therapeutic efficacy and an acceptable safety profile. At the same time, they must manage escalating costs, lengthy timelines, and increasing expectations from regulators, payers, and patients. Despite […] The post Four Ways Pharmaceutical Companies Are De-Risking R&D...| COTA Healthcare
Cancer affects everyone, including adolescents and young adults who are at increasing risk of developing certain types of disease. It’s a particularly challenging time of life to receive a cancer diagnosis. Many cancers in younger patients can be aggressive, and treatment can be complicated, expensive, painful, and isolating for young people who should be focused […] The post Sounds of Support: COTA & Friends Unite for Young Adults with Cancer appeared first on COTA Healthcare.| COTA Healthcare
COTA’s real-world data is featured in nine abstracts at the European Hematology Association (EHA) 2025 Congress to support meaningful, evidence-based research across a range of hematologic diseases.| COTA Healthcare
The annual meeting of the American Society of Clinical Oncology (ASCO) is a chance for oncology professionals, patient advocates, data experts, and industry representatives to come together and share the latest research in cancer care.This year, thousands of attendees descended on Chicago to attend educational sessions, view research posters, collaborate in workshops, and strengthen connections with colleagues across five days of non-stop learning.| COTA Healthcare
Each year, ISPOR brings together members of the health economics and outcomes research (HEOR) community for a celebration of the latest research and innovative methodology to push forward data-driven, patient-centered decision-making across the life sciences. It’s an event that never disappoints. Between the presentations of innovative research projects, experts sharing their knowledge in information sessions, […] The post Reflections on ISPOR: Shifting data dynamics open new opportunitie...| COTA Healthcare
By furthering our investment in women’s cancer datasets, COTA is eager to collaborate with industry partners on accelerating research into these conditions with the goal of improving experiences and outcomes for the hundreds of thousands of women affected by cancer every year.| COTA Healthcare
We’re setting our sights on solid tumors to bring even more clarity and understanding to the cancer community. Our datasets now include longitudinal treatment and outcomes data for a broad array of solid tumors.| COTA Healthcare
Since the turn of the century, there’s been a growing recognition that the health of our friends, families, & communities is intimately tied to the health of our physical environment. Safe water, clean air, & a diverse, balanced ecosystem are essential conditions for life to thrive & innovation to flourish.As a company focused on healthcare […]| COTA Healthcare
CAILIN addresses these questions through training on COTA's proprietary datasets while guided by in-house oncology expertise. CAILIN expedites access to data and oncology-specific insights across the pharmaceutical R&D life cycle and, in the near future, will provide additional ways to develop hypotheses and generate evidence.| COTA Healthcare
